VIIBRYD Drug Patent Profile
✉ Email this page to a colleague
When do Viibryd patents expire, and when can generic versions of Viibryd launch?
Viibryd is a drug marketed by Allergan and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.
This drug has sixty patent family members in twenty-nine countries.
The generic ingredient in VIIBRYD is vilazodone hydrochloride. There are fourteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the vilazodone hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Viibryd
A generic version of VIIBRYD was approved as vilazodone hydrochloride by ALEMBIC PHARMS LTD on January 10th, 2020.
Summary for VIIBRYD
International Patents: | 60 |
US Patents: | 4 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 77 |
Clinical Trials: | 16 |
Patent Applications: | 129 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for VIIBRYD |
Drug Sales Revenues: | Drug sales revenues for VIIBRYD |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for VIIBRYD |
What excipients (inactive ingredients) are in VIIBRYD? | VIIBRYD excipients list |
DailyMed Link: | VIIBRYD at DailyMed |



Recent Clinical Trials for VIIBRYD
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Forest Laboratories | Phase 1 |
New York State Psychiatric Institute | Phase 4 |
Forest Laboratories | Phase 3 |
Anatomical Therapeutic Chemical (ATC) Classes for VIIBRYD
Paragraph IV (Patent) Challenges for VIIBRYD
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
VIIBRYD | Tablets | vilazodone hydrochloride | 10 mg, 20 mg, and 40 mg | 022567 | 5 | 2015-01-21 |
US Patents and Regulatory Information for VIIBRYD
VIIBRYD is protected by four US patents and two FDA Regulatory Exclusivities.
Patents protecting VIIBRYD
Polymorphic forms of 1-'4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Polymorphic forms of 1-'4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
FDA Regulatory Exclusivity protecting VIIBRYD
INFORMATION ADDED TO THE LABELING REGARDING PEDIATRIC PATIENTS AGES 7 TO 17 YEARS OF AGE WITH MAJOR DEPRESSIVE DISORDER
Exclusivity Expiration: See Plans and Pricing
PEDIATRIC EXCLUSIVITY
Exclusivity Expiration: See Plans and Pricing
Expired US Patents for VIIBRYD
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Allergan | VIIBRYD | vilazodone hydrochloride | TABLET;ORAL | 022567-002 | Jan 21, 2011 | See Plans and Pricing | See Plans and Pricing |
Allergan | VIIBRYD | vilazodone hydrochloride | TABLET;ORAL | 022567-001 | Jan 21, 2011 | See Plans and Pricing | See Plans and Pricing |
Allergan | VIIBRYD | vilazodone hydrochloride | TABLET;ORAL | 022567-003 | Jan 21, 2011 | See Plans and Pricing | See Plans and Pricing |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for VIIBRYD
See the table below for patents covering VIIBRYD around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Japan | 2010132688 | POLYMORPHIC FORM OF 1-4-(5-CYANOINDOL-3-YL)BUTYL-4-(2-CARBAMOYLBENZOFURAN-5-YL)PIPERAZINE HYDROCHLORIDE | See Plans and Pricing |
Ukraine | 76758 | ПОЛИМОРФНЫЕ ФОРМЫ ГИДРОХЛОРИДА 1-[4-(5-ЦИАНОИНДОЛ-3-ИЛ)БУТИЛ]-4-(2-КАРБАМОИЛБЕНЗОФУРАН-5-ИЛ)-ПИПЕРАЗИНА;ПОЛІМОРФНІ ФОРМИ ГІДРОХЛОРИДУ 1-'4-(5-ЦІАНОІНДОЛ-3-ІЛ)БУТИЛ-4-(2-КАРБАМОЇЛБЕНЗОФУРАН-5-ІЛ)ПІПЕРАЗИНУ (POLYMORPH FORMS OF HYDROCHLORIDE OF 1-[4-(5-CYANOINDOL-3-YL)BUTYL]-4-(2-CARBAMOYL-BENZOFURAN-5-YL)-PIPERAZINE) | See Plans and Pricing |
Germany | 59402902 | See Plans and Pricing | |
Spain | 2105454 | See Plans and Pricing | |
Canada | 2782615 | See Plans and Pricing | |
>Country | >Patent Number | >Title | >Estimated Expiration |